* Pliant Therapeutics Inc PLRX.OQ PLRX.O is expected
to show a
fall in quarterly revenue when it reports results on May 8
(estimated).
* The South San Francisco California-based company is
expected to
report a 2.8% decrease in revenue to $1.214 million from $1.25
million a year ago, according to the mean estimate from 8
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Pliant Therapeutics
Inc
is for a loss of 67 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Pliant
Therapeutics Inc is $45, above its last closing price
of $22.68.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.70 -0.70 -0.72 Missed -2.8
Sep. 30 2022 -0.74 -0.74 -0.65 Beat 12.3
Jun. 30 2022 -0.82 -0.81 -0.82 Missed -1
Mar. 31 2022 -0.73 -0.75 -0.78 Missed -4
Dec. -0.76 -0.76 -0.68 Beat 10.4
31 2021
Sep. 30 2021 -0.68 -0.69 -0.75 Missed -8.7
Jun. 30 2021 -0.67 -0.67 -0.64 Beat 4.4
Mar. 31 2021 -0.64 -0.60 -0.64 Missed -6
This summary was machine generated May 5 at 12:35 GMT. All
figures in US dollars unless otherwise stated